Carl Byrnes
Stock Analyst at Northland Securities
(0.32)
# 4,393
Out of 4,630 analysts
284
Total ratings
37.5%
Success rate
-3.3%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings | Maintained: Buy | $7.5 | $2.21 | +240.14% | 3 | Apr 24, 2026 | |
| MDXG MiMedx Group | Maintained: Buy | $10 → $6 | $4.34 | +38.25% | 27 | Apr 17, 2026 | |
| SPRY ARS Pharmaceuticals | Maintained: Buy | $25 | $6.16 | +305.84% | 2 | Apr 15, 2026 | |
| RCEL AVITA Medical | Maintained: Buy | $10 | $7.77 | +28.70% | 2 | Mar 26, 2026 | |
| BLFS BioLife Solutions | Reiterated: Buy | $34 | $34.66 | -1.90% | 37 | Mar 24, 2026 | |
| TLSI TriSalus Life Sciences | Rated: Buy | $13 → $8 | $5.61 | +42.60% | 5 | Mar 23, 2026 | |
| MDAI Spectral AI | Maintained: Buy | $6 | $1.75 | +242.86% | 12 | Mar 19, 2026 | |
| SNWV SANUWAVE Health | Maintained: Buy | $55 | $5.88 | +835.37% | 4 | Mar 16, 2026 | |
| INDV Indivior Pharmaceuticals | Maintained: Buy | $50 | $38.82 | +28.80% | 12 | Feb 27, 2026 | |
| BWAY BrainsWay | Maintained: Buy | $12 → $15 | $15.50 | -3.23% | 14 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.81 | +162.47% | 18 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $4 | $0.4908 | +715.00% | 39 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.6712 | +644.93% | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $2 → $1.25 | $14.36 | n/a | 12 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $1.79 | n/a | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $8 → $1 | $0.0001 | n/a | 24 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $2 | $0.0001 | n/a | 24 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 → $2 | $34.99 | n/a | 30 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.36 | n/a | 12 | May 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $45 | $64.72 | n/a | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $14.38 | n/a | 1 | Oct 22, 2018 |
Connect Biopharma Holdings
Apr 24, 2026
Maintained: Buy
Price Target: $7.5
Current: $2.21
Upside: +240.14%
MiMedx Group
Apr 17, 2026
Maintained: Buy
Price Target: $10 → $6
Current: $4.34
Upside: +38.25%
ARS Pharmaceuticals
Apr 15, 2026
Maintained: Buy
Price Target: $25
Current: $6.16
Upside: +305.84%
AVITA Medical
Mar 26, 2026
Maintained: Buy
Price Target: $10
Current: $7.77
Upside: +28.70%
BioLife Solutions
Mar 24, 2026
Reiterated: Buy
Price Target: $34
Current: $34.66
Upside: -1.90%
TriSalus Life Sciences
Mar 23, 2026
Rated: Buy
Price Target: $13 → $8
Current: $5.61
Upside: +42.60%
Spectral AI
Mar 19, 2026
Maintained: Buy
Price Target: $6
Current: $1.75
Upside: +242.86%
SANUWAVE Health
Mar 16, 2026
Maintained: Buy
Price Target: $55
Current: $5.88
Upside: +835.37%
Indivior Pharmaceuticals
Feb 27, 2026
Maintained: Buy
Price Target: $50
Current: $38.82
Upside: +28.80%
BrainsWay
Jan 22, 2026
Maintained: Buy
Price Target: $12 → $15
Current: $15.50
Upside: -3.23%
Nov 14, 2025
Maintained: Buy
Price Target: $10
Current: $3.81
Upside: +162.47%
Nov 5, 2025
Reiterated: Buy
Price Target: $9 → $4
Current: $0.4908
Upside: +715.00%
Aug 28, 2025
Maintained: Buy
Price Target: $5
Current: $0.6712
Upside: +644.93%
Jul 19, 2023
Rated: Hold
Price Target: $2 → $1.25
Current: $14.36
Upside: n/a
May 22, 2023
Initiated Coverage: Buy
Price Target: $8
Current: $1.79
Upside: n/a
Jan 6, 2023
Downgraded: Sell
Price Target: $8 → $1
Current: $0.0001
Upside: n/a
Nov 23, 2022
Maintained: Buy
Price Target: $10 → $2
Current: $0.0001
Upside: n/a
Aug 17, 2022
Maintained: Buy
Price Target: $4 → $2
Current: $34.99
Upside: n/a
May 14, 2020
Rated: Hold
Price Target: n/a
Current: $2.36
Upside: n/a
Oct 22, 2018
Initiated Coverage: Buy
Price Target: $45
Current: $64.72
Upside: n/a
Oct 22, 2018
Initiated Coverage: Buy
Price Target: n/a
Current: $14.38
Upside: n/a